Gene therapy offers to beat hepatitis B virus by muting its DNA
An experimental therapy called CRMA-1001 is a remarkable development because, instead of targeting the virus directly, it silences the viral DNA; this is promising because current treatments rarely eliminate the DNA, which allows the virus to rebound
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The article discusses the potential of gene therapy to treat the hepatitis B virus (HBV) by modifying its DNA. Specifically, it highlights the historical discovery of 5-methylcytosine, a modified DNA building block, which is relevant to current research exploring gene-editing techniques to 'mute' or silence the virus's genetic material.
UPSC Perspectives
Science & Technology
The potential use of gene therapy against Hepatitis B is a significant development in biotechnology. Gene therapy involves modifying a patient's genes to treat or cure a disease, often replacing a faulty gene or adding a new one. The article touches upon the concept of DNA methylation, specifically the role of 5-methylcytosine. Methylation is an epigenetic mechanism—a process that alters gene expression without changing the underlying DNA sequence. In the context of HBV, researchers are exploring how to use techniques like to target the virus's DNA and potentially use methylation or other gene-silencing methods to 'mute' its activity. UPSC Prelims frequently tests understanding of basic biotechnological concepts, the difference between DNA and RNA, and the mechanisms of emerging therapies like gene editing.
Public Health
Hepatitis B is a major global public health concern, causing chronic liver infections that can lead to cirrhosis and liver cancer. Current treatments, mainly antiviral medications, can control the virus but rarely cure it because the virus establishes a persistent form of DNA (cccDNA) in the liver cells. A gene therapy approach that successfully 'mutes' the HBV DNA could represent a functional cure, significantly reducing the global disease burden. The has set targets for eliminating viral hepatitis as a public health threat by 2030. In India, the aims to provide free screening and treatment for Hepatitis B and C. Understanding the limitations of current treatments and the potential of new therapies is crucial for GS Paper 3 (Science and Technology) and GS Paper 2 (Issues relating to Health).
Research & Innovation
The article highlights the cumulative nature of scientific discovery, referencing the synthesis of 5-methylcytosine in 1904. This illustrates how foundational research in biochemistry can eventually lead to advanced therapeutic applications decades later. The development of gene therapies requires robust research infrastructure, significant funding, and clear regulatory frameworks. In India, the plays a key role in promoting such research. The translation of this basic science into clinical applications involves rigorous trials to ensure safety and efficacy. For UPSC Mains, discussing the importance of sustained investment in basic science research and the challenges in moving from the laboratory to clinical practice is a relevant theme.